Calibrate Weight Loss Quick Answer
Calibrate weight loss is a US-only subscription programme that combines a prescribed GLP-1 medicine with video coaching and a habits curriculum. Its pricing page lists $199 a month with a 3-month minimum, and medicine is billed separately through insurance. Calibrate reports an average 16.2% loss at 12 months in one cohort, but that figure comes from a company press release, not a peer-reviewed study. Medicine trials show similar results, and weight often returns when treatment stops.
Disclosure: HealthCoachJP has no commercial relationship with Calibrate, and this page contains no affiliate links. We do not endorse the programme. This review is factual and compares claims with published evidence. Our wider guide to medical weight loss explains the other routes.
What the Programme Includes
Calibrate calls its offer the Metabolic Reset. Members take an eligibility quiz and then complete a health intake form. Coaching, blood work and a first virtual clinician visit follow within about two weeks.
The company says its clinicians prescribe GLP-1 medicines, including tirzepatide and semaglutide products. The membership covers a clinician visit with lab review, ongoing access to a medical and support team, insurance navigation, one-to-one video coaching, app tools and a smart scale.
The curriculum runs in four phases over the first year. It covers food, exercise, sleep and emotional health. For background on those pillars, see our guides on sleep and weight loss and stress and weight.
Calibrate Weight Loss Cost in 2026
The cost has two parts. The programme fee goes to Calibrate. The medicine is billed under your insurance plan, so your out-of-pocket price depends on your coverage.
| Cost item | What Calibrate states | What to check |
|---|---|---|
| Programme fee | $199 a month, 3-month minimum ($597 total), then monthly | Cancellation terms before you pay |
| Medicine | Not in the fee. Copays are typically $25 a month or less after any deductible for most commercial plans | Whether your plan covers weight loss use |
| Insurance for the fee | Not covered, but HSA and FSA eligible | Your plan rules |
| Guarantee | 10% weight loss or eligibility for money back | The full guarantee terms, which we could not review |
Sources: Calibrate pricing page and how it works page. Prices change often, so confirm them on the company site. Earlier published figures, such as a $1,749 yearly fee in 2023 trade press, no longer match the current page.
Without coverage, a branded GLP-1 can cost far more than the programme fee. We did not find an authoritative price for the medicine alone. Ask your insurer before you enrol.
Who Can Join the Programme
Eligibility is set by the company and is not a medical rule. The page we reviewed lists these criteria.
- Age 18 or older and a US resident.
- BMI of 30 or higher, or 27 or higher with a listed condition such as prediabetes, high blood pressure, high cholesterol or sleep apnoea.
- Not eligible: pregnancy or breastfeeding, active eating disorder or substance misuse, current cancer treatment, recent bariatric surgery, active gallbladder disease, recent pancreatitis, or a personal or family history of medullary thyroid cancer.
Check your own number with our BMI explainer, and remember it is only a screening tool. Calibrate is US-only. If you live in the UK, access to these medicines runs through the NHS, covered below.
Why Calibrate Weight Loss Figures Disagree
Several Calibrate numbers circulate, and they do not match. Each comes from a different group and a different date.
| Source | Reported average loss | Who was counted |
|---|---|---|
| Calibrate press release, Oct 2023 | 16.2% at 12 months | 11,429 members; company-reported, not peer reviewed |
| Same release | 17.2% at 24 months | Only 650 members, about 6% of the 12-month group |
| Calibrate press release, Jan 2025 | 19% at 36 months | 17,000+ members; method not described |
| Calibrate how-it-works page | 16%, 18% and 20% at 12, 24 and 36 months | Cites a results report; the page header says 19% |
| STEP 1 trial, semaglutide | 14.9% at 68 weeks | Randomised trial with lifestyle support |
| SURMOUNT-1 trial, tirzepatide | Up to 20.9% at 72 weeks | Randomised trial with lifestyle support |
Three problems explain the gap. First, the 24-month group is small and may be people who stayed on treatment. Second, the company data is not peer reviewed and gives no comparison group. Third, trials and real-world data measure different people. Sources: 2023 release, 2025 release, STEP 1 and SURMOUNT-1.
In short, the medicine likely drives most of the result. The coaching may help people stay on treatment, but the data do not separate the two.
What Metabolic Reset Really Means
Calibrate describes its programme as resetting your metabolism. That is a marketing phrase, not a clinical term. The FDA label for semaglutide describes a different mechanism. It says GLP-1 is a regulator of appetite and calorie intake, that the drug delays gastric emptying, and that it decreases calorie intake.
So the medicine lowers appetite. It does not speed up your metabolism, as some marketing claims suggest. Studies of metabolic slowing after weight loss are mixed. One NIH study of 14 Biggest Loser contestants found a large, persistent drop in resting metabolic rate. Other analyses conclude adaptation is not a major barrier to keeping weight off.
Read more in our guide to metabolism and weight loss. Source for the contestant study: Healio summary.
Calibrate Weight Loss Pros and Cons
| Pros | Cons |
|---|---|
| Clinician visits, labs and coaching in one subscription | Programme fee is separate from medicine costs |
| Handles insurance navigation, including prior authorisation | Works best if your insurer covers GLP-1 medicines |
| Can cancel after the 3-month minimum | Company results are unreviewed and inconsistent between pages |
| Structured habits curriculum on food, sleep, exercise and emotions | US residents only, with a long exclusion list |
| Medicines in this class have strong trial evidence | Weight tends to return after stopping the medicine |
Whether it is worth it depends on your coverage, your clinician and how much structure you want. A local doctor can prescribe the same medicines without a subscription. Compare options with our Ozempic guide.
Calibrate Weight Loss Safety and Side Effects
Risks come from the medicine, not the coaching. The semaglutide label (Wegovy, revised March 2026) carries a boxed warning about thyroid C-cell tumours seen in rodents. The drug is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Other label warnings include pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, and kidney injury from dehydration. The label says the drug may cause fetal harm and should be stopped when pregnancy is recognised. Tell your clinician about any planned surgery or sedation.
The most common reactions in adults on Wegovy were nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%) and abdominal pain (20%). Check the label of whichever medicine you are prescribed. See how diabetes medicines affect weight if you use insulin.
Never stop or change another medicine because of a weight programme. If you have, or have had, an eating disorder, speak to a clinician first. In the US, the National Alliance for Eating Disorders offers support, and you can call or text 988 in a crisis. In the UK, Samaritans is on 116 123.
Weight Regain and UK Options
In the STEP 1 extension, people stopped semaglutide and were followed for a year. They regained about two-thirds of the weight they had lost. That is why maintenance habits matter, and why a one-year programme is not a cure.
In the UK, Calibrate is not available. NHS England says semaglutide is prescribed through specialist weight management services. Tirzepatide is being phased in for people with the highest clinical need. NICE modelled a two-year maximum for semaglutide. Access varies by local NHS area, as covered in NHS England and NICE guidance.
What the Evidence Says About Calibrate Claims
| Claim | Where it stands | Reader guidance |
|---|---|---|
| The programme resets your metabolism | Not supported | The label describes reduced appetite and calorie intake, not a faster metabolism. |
| GLP-1 medicines speed up metabolism | Not supported | The FDA label says they reduce appetite and delay gastric emptying. |
| Weight stays off for good | Overstated | In the STEP 1 extension, about two-thirds of lost weight returned within a year of stopping. |
| Members average 16 to 20% loss | Unverified | Company figures vary by page and are not peer reviewed. Trials show 14.9 to 20.9%. |
| Eligible members will be prescribed a GLP-1 | Partly supported | Clinicians decide. Eligibility and medical history still apply. |
| Prices are fully transparent | Partly supported | The fee is clear, but medicine costs depend on your insurance. |
| The programme is based on science | Partly supported | Medicines have trial evidence. The coaching curriculum has no independent trial that we found. |
Calibrate Weight Loss FAQ
It is a US subscription programme that pairs a prescribed GLP-1 medicine with video coaching and a curriculum on food, sleep, exercise and emotional health.
The pricing page lists 199 dollars a month with a 3-month minimum. Medicine is billed separately through insurance. Confirm current prices on the company site.
US adults aged 18 or older with a BMI of 30 or higher, or 27 or higher with a listed condition. Several health conditions and pregnancy exclude people.
Calibrate reports 16.2 percent at 12 months in one cohort. These are company figures that were not peer reviewed and vary between pages.
No evidence shows this. The FDA label says semaglutide reduces appetite and calorie intake and delays gastric emptying.
Nausea, diarrhoea, vomiting and constipation are most common. The label also warns about pancreatitis, gallbladder disease and thyroid tumours seen in rodents.
Often, yes. In the STEP 1 extension, people regained about two-thirds of the weight lost in the year after stopping semaglutide.
No. In the UK, NHS specialist weight management services prescribe these medicines, and access varies by area.
No. We have no commercial relationship with Calibrate, and this page has no affiliate links.
Related Reading
- Medical weight loss: what it is, results and risks
- Ozempic for weight loss: approval, dose, cost and risks
- How to spot a fad diet
- Sustainable weight loss tips that last
Sources
- Calibrate: pricing page
- Calibrate: how it works
- Business Wire: Calibrate 2023 results press release
- Business Wire: Calibrate 2025 results press release
- MedCity News: Calibrate restructuring
- FDA: Wegovy prescribing information (revised 03/2026)
- ACC: STEP 1 trial summary
- NEJM: Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
- Wilding et al.: Weight regain after withdrawal of semaglutide, STEP 1 extension
- Healio: Metabolic adaptation persists after weight loss
- NICE: semaglutide for managing overweight and obesity
- NHS England: Weight management injections
Written and fact-checked by the HealthCoachJP editorial team. No clinician has reviewed this article. See our sources cited page. Last reviewed and rewritten October 2026.
Medical disclaimer: this article is general information, not medical advice. Talk to a doctor or pharmacist before starting, stopping or combining any medicine.
